Radiation for prostate cancer linked to secondary cancers, study finds

May 30, 2014

ANN ARBOR, Mich. -- Among men treated for prostate cancer, those who received radiation therapy were more likely to develop bladder or rectal cancer, according to a new study from the University of Michigan Comprehensive Cancer Center.

"Overall the incidence of these cancers is low. But when men have received radiation treatments, it's important to evaluate carefully any symptoms that could be a sign of bladder or rectal cancer," says senior study author Kathleen A. Cooney, M.D., professor of hematology/oncology and urology at the U-M Medical School.

The study, which will be presented at the American Society of Clinical Oncology annual meeting, looked at 441,504 men diagnosed with prostate cancer between 1992 and 2010. Men were identified from the Surveillance, Epidemiology and End Results (SEER) program, a network of National Cancer Institute-sponsored, population-based cancer registries that collect information on cancer diagnoses and treatment. SEER performs regular follow-up for survival and to capture new invasive cancer diagnoses.

The researchers looked at the number of secondary cancers that developed 10 or more years after men were diagnosed with prostate cancer. As a whole, men diagnosed with prostate cancer were at a lower risk of developing a second cancer. But when researchers looked at patients who received external beam radiation therapy, they found these patients were estimated to be 70 percent more likely to be diagnosed with a rectal cancer and 40 percent more likely for bladder cancer than the general public.

Radiation therapy is a standard treatment for prostate cancer and the researchers stress that their findings should not prohibit anyone from choosing this treatment, in particular men who are not good candidates for surgery.

"Prostate cancer has an excellent prognosis. But because patients typically survive a long time, it raises concerns about the risk of second cancers," says study author Elizabeth J. Davis, M.D., a fellow at the U-M Medical School. "Long-term survivors who have undergone treatment with radiation and their physicians should be careful to monitor for symptoms of bladder and rectal cancer."
-end-
Full results of the study were published online in Cancer.

Additional authors: Cecilia Yee M.S., Jennifer Beebe-Dimmer M.P.H, Ph.D., both of Karmanos Cancer Institute and Wayne State University School of Medicine

Funding: National Institutes of Health grants P50 CA69568, HHSN261201300011I and P30 CA022453

Disclosure: None

Reference: American Society of Clinical Oncology annual meeting, May 30-June 3, 2014, abstract No. 5034; Cancer, DOI: 10.1002/cncr.28769

Resources:

U-M Cancer AnswerLine, 800-865-1125

U-M Comprehensive Cancer Center, http://www.mcancer.org

Clinical trials at U-M, http://www.mcancer.org/clinicaltrials

mCancerTalk blog, http://uofmhealthblogs.org/cancer

University of Michigan Health System

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.